Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should AbbVie Be Worried About Rinvoq?

TheMotleyFool

0 0

The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq.

Source Fool.com

Like: 0

ABBV

Share